💨 Abstract

President Trump's proposed tariffs on pharmaceutical imports could affect India's pharma exports, which are mainly generics and amounted to $9 billion last fiscal year. However, Indian drugmakers like Dr. Reddy's and Piramal Pharma are confident they will remain competitive due to practical manufacturing limitations and cost issues in the U.S. They are hopeful for bilateral talks to secure an exception.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖